0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Growth Hormone Treatment in Turner Syndrome: Results of a Multicentre Study in Japan

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with Turner syndrome were treated with recombinant human growth hormone (GH) for 3 years. Sixty-eight patients received GH, 0.5 IU/kg/week, while 93 received GH, 1.0 IU/kg/week, by daily subcutaneous injection. Both treatment groups showed a statistically significant increase in growth during treatment. However, the higher dose increased height velocity to a significantly greater extent during the first and second year of treatment. The projected adult height was exceeded by 52 of 71 patients over the age of 14 years. Plasma insulin-like growth factor 1 levels were elevated and no remarkable advances in bone age were observed. There were no other significant changes in physical or laboratory parameters. No glucose intolerance was observed. These results indicate that GH treatment is useful for accelerating growth velocity in patients with Turner syndrome. However, further study will be required to find the most appropriate dose.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5795-5
          978-3-318-01951-3
          1663-2818
          1663-2826
          1993
          1993
          03 December 2008
          : 39
          : Suppl 2
          : 37-41
          Affiliations
          aDepartment of Medicine, Institute of Clinical Endocrinology, Tokyo Women’s Medical College, and bThe Foundation for Growth Science in Japan, Tokyo, Japan
          Article
          182766 Horm Res 1993;39:37–41
          10.1159/000182766
          8359787
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Session II Dosing hGH in Turner Syndrome

          Comments

          Comment on this article